38th week of 2008 patent applcation highlights part 40 |
Patent application number | Title | Published |
20080226668 | Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes - The present invention regards methods and formulations for the treatment of diabetes and the prevention of autoimmune diabetes. The invention includes the administration of human recombinant GAD65 protein in a pharmaceutically acceptable adjuvant. | 2008-09-18 |
20080226669 | MULTIVALENT PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine, | 2008-09-18 |
20080226670 | CANINE COMBINATION VACCINES - This invention relates to vaccines and methods for protecting dogs against disease caused by | 2008-09-18 |
20080226671 | Vaccines for Mycoplasma bovis and methods of use - The invention of novel, effective vaccines against | 2008-09-18 |
20080226672 | Adjuvant Systems and Vaccines - An adjuvant composition comprising monophosphoryl lipid A or a derivative of monophposphoryl lipid A adsorbed onto an aluminium salt particle. | 2008-09-18 |
20080226673 | SUBUNIT VACCINE AGAINST RESPIRATORY SYNCYTIAL VIRUS INFECTION - The present invention relates generally to methods of treating or preventing RSV infections, and more specifically, to compositions, and the use thereof, comprising one or more RSV G protein immunogen or fragment thereof capable of eliciting protective immunity without eliciting an immunopathological response or eliciting a reduced immunopathological response. | 2008-09-18 |
20080226674 | Composition Having Antitumor Effect - The present invention is intended to provide a pharmaceutical composition for delivering a chemotherapeutic, preferably an anticancer drug, into cells or into a living organism, using a viral envelope vector, and provides a pharmaceutical composition comprising a chemotherapeutic encapsulated in, or used in combination with, a viral envelope vector having an adjuvanticity as an active ingredient. Thereby it is possible to introduce an anticancer drug encapsulated in a viral envelope vector directly into a tumor, with coadministration of another anticancer drug so as to induce tumor cell-specific antitumor immunity also thanks to the adjuvant action of HVJ-E, and hence to regress the tumor. The present invention also provides a pharmaceutical composition comprising a viral envelope vector and a chemotherapeutic as active ingredients. | 2008-09-18 |
20080226675 | RECOMBINANT VECTOR AND USE IN GENE THERAPY - A recombinant vector for delivering A3G genes into human cells comprising (i) a gene expression block including an A3G gene selected from a wild type A3G gene represented by SEQ ID NO: 1 and a mutant A3G gene and (ii) a group of elements from a modified lentiviral vector including lentiviral regions of packaging signal (ψ, psi), LTRs, RRE, and PBS; wherein said A3G gene is operably linked to the packaging signal (ψ, psi), LTRs, RRE, and PBS. | 2008-09-18 |
20080226676 | Multivalent avian influenza vaccines and methods - The present invention provides vaccine compositions comprising at least two strains of avian influenza virus, wherein one of the strains has an H5 hemagglutinin subtype and the other strain has an H7 hemagglutinin subtype, and wherein at least one of the strains has an N4 neuraminidase subtype and neither strain has an N1 subtype. Also provided are vaccination methods that utilize the novel vaccine compositions of the invention. The compositions and methods of the present invention provide protection against infection with H5 and H7 influenza strains (e.g., H5N1 and H7N1) while at the same time facilitating the distinction between infected and vaccinated animals. | 2008-09-18 |
20080226677 | Recombinant virus vector for gene transfer into lymphoid cells - A recombinant herpesvirus, a method for producing the recombinant herpesvirus, and a pharmaceutical composition comprising the recombinant herpesvirus, are provided with a method for producing a recombinant herpesvirus using a BAC vector sequence. In addition, a vector comprising a herpesvirus genomic gene and a BAC vector sequence, a cell comprising the vector, and a nucleic acid cassette comprising a fragment, which is capable of homologous recombination with a herpesvirus genome, and a BAC vector sequence, are provided. | 2008-09-18 |
20080226678 | Compositions for Immunizing Against Mycobacterium - A method for generating a T cell immune response in a host involving administering a vectored vaccine comprising a non-replicating or replication impaired viral vector expressing the translation product of a mycobacterial antigen 85A gene. Vectored vaccines and uses thereof are also provided. Also provided is a method of inducing a CD8 and a CD4 memory T cell response against an antigen using an adenovirus vector expressing an antigen or an immunogenic fragment thereof. | 2008-09-18 |
20080226679 | Novel surface exposed proteins from chlamydia pneumoniae - The invention relates to the identification of members of a gene family from the human respiratory pathogen | 2008-09-18 |
20080226680 | Method and composition for delivery of medicants to animals - According to the present invention, a vaccine or pharmaceutical-containing composition is applied to the muzzle area of the animal, which will then naturally use its tongue to clean itself. This behavior will cause the animal to deposit applied composition to the mucosa of the nasal and oral cavities, thus meeting the need for a simple, effective, and efficient vaccination or treatment method. | 2008-09-18 |
20080226681 | Highly Active Glycoproteins-Process Conditions and an Efficient Method for their Production - The present invention relates to highly active glycoproteins with specific sialylation degrees, a pharmaceutical composition for use in diagnosis or therapy comprising the glycoproteins, a method for the determination of highly active glycoproteins and of the conditions for their production, a method for producing the highly active glycoproteins, and a method for differential sialylation of secretory glycoproteins. The invention also relates to the use of the recombinantly expressed highly active glycoproteins for biological purposes and for prophylactic and/or therapeutic treatment or diagnosis of diseases, particularly bone marrow transplantation, neutropenia, cytopenia, AML and myelodysplastic syndromes, cancer, HIV and/or diseases of hematopoietic systems. | 2008-09-18 |
20080226682 | Immunoactive Compositions for Improved Oral Delivery of Vaccines and Therapeutic Agents - The present invention concerns methods and compositions for improved oral delivery of bioactive agents, such as vaccines. In preferred embodiments, the compositions comprise at least one lectin, saponin, polyunsaturated fatty acid and/or isoflavone. In further embodiments, the compositions may further comprise at least one protease inhibitor, buffer and/or surfactant. In more preferred embodiments, the lectins, saponins, fatty acids, isoflavones and/or protease inhibitors may be derived from extracts, homogenates, finely ground powders or derivatives of plant or animal material, such as beans, nuts, peas, fish meal or krill. The relative amounts of various naturally occurring materials contained in the compositions may be selected to optimize the concentrations of one or more lectins, saponins, polyunsaturated fatty acids and/or isoflavones. The compositions are of use for oral delivery of a wide variety of bioactive agents, particularly protein or peptide based agents. | 2008-09-18 |
20080226683 | Pharmaceutical Composition Including Clinoptilolite - The invention is for a method of potentiating clinoptilolite, the method including the steps of: providing fresh or spent clinoptilolite; exposing the clinoptilolite to a saline solution having a sodium ion content of about 10% to liberate impurities from the clinoptilolite; and drying the washed clinoptilolite fraction to render a potentiated clinoptilolite fraction. Preferably, the clinoptilolite is exposed to the saline solution for a period of about 48 hours. The washed clinoptilolite may be dried by filtered, heated air. This allows an optimal cation exchange capacity of the clinoptilolite to be reached. The clinoptilolite has uses as a medicament for a variety of aliments. | 2008-09-18 |
20080226684 | METHOD AND PROCESS FOR THE PRODUCTION OF MULTI-COATED RECOGNITIVE AND RELEASING SYSTEMS - The present invention includes compositions, methods, systems and kits for the controlled delivery of an active agent within a polymeric network upon the binding of a molecule that decreases the structural integrity of the polymeric network at one or more micro- or nanovacuoles. | 2008-09-18 |
20080226685 | Product and Method for Controlling Flying Insects - Insect control articles and methods of controlling insects comprising a cellulosic based substrate or matrix having a specified surface area impregnated and/or dosed with a vapour active pyrethroid in a carrier solvent, such that the vapour active pyrethroid is emanated into the environment at a rate of at least approximately 0.040 mg/h at a temperature of approximately 18-40° C. | 2008-09-18 |
20080226686 | GENERATION OF NITRIC OXIDE IN SITU AT SUBSTRATE/BLOOD INTERFACES AND REPRODUCIBLE NITRIC OXIDE SENSOR FOR DETECTING NITROSOTHIOLS - A material includes a surface and a reactive agent that is located at the surface of the material, covalently attached to a backbone of the material, and/or located within the material. The reactive agent has nitrite reductase activity, nitrate reductase activity, and/or nitrosothiol reductase activity. The reactive agent also converts at least one of nitrites, nitrates and nitrosothiols to nitric oxide when in contact with blood. A reproducible nitrosothiol sensor is also disclosed. | 2008-09-18 |
20080226687 | Drug delivery and method having coated microprojections incorporating vasoconstrictors - A device and method are provided for percutaneous transdermal delivery of a biologically active agent. The coating formulation containing the biologically active agent and a vasoconstrictor is applied to the skin piercing elements using known coating techniques and then dried. The device is applied to the skin of a living animal, causing the microprojections to pierce the stratum corneum and to deliver an effective dose of the biologically active agent and vasoconstrictor to the animal. | 2008-09-18 |
20080226688 | Ceramic composition for filling bone defects - The invention is directed toward a sterile formable implant composition for application to a bone defect site comprising bioactive glass particles in an aqueous carrier solution, the bioactive glass particles being added to a viscous carrier at a concentration ranging from about 68% to about 76% (w/w), the carrier comprising a mixture of glycerol and polyethylene glycol ranging from 24% to 32% (w/w) with the ratio of glycerol to polyethylene glycol ranging from about 45:55 to about 65:35. | 2008-09-18 |
20080226689 | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles - This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1×10 | 2008-09-18 |
20080226690 | Heparosan-based biomaterials and coatings and methods of production and use thereof - The presently claimed and disclosed invention relates to biomaterial compositions that include an isolated heparosan polymer. The presently claimed and disclosed invention also relates to kits containing such biomaterial compositions, as well as to methods of producing such biomaterial compositions. The presently claimed and disclosed invention further relates to methods of using such biomaterial compositions as surface coatings for implants as well as for augmenting tissues. | 2008-09-18 |
20080226691 | BONE CEMENT COMPOSITIONS HAVING FIBER-REINFORCEMENT AND/OR INCREASED FLOWABILITY - The present invention relates in general to implantable compositions, and method for preparing same, containing a calcium salt-containing component, optionally demineralized bone, a plurality of discrete fibers, optionally a flow additive, and optionally continuous reinforcing fibers or an array of organized fibers in the form of mesh. Advantageously, the discrete fibers have a specific aspect ratio (length/diameter) from about 50:1 to about 1000:1. The addition of a small amount of discrete fibers and/or the continuous reinforcing fibers or fiber mesh can cause drastic increases in certain mechanical properties including flexural strength, flexural toughness, and/or screw pullout strength. | 2008-09-18 |
20080226692 | Cultured Cell Sheet, Production Method Thereof, and Application Method Thereof - The problem to be solved by the present invention is to provide a cultured cell sheet that expresses phenotypes of the chondroid tissue. The problems can be solved by producing the cultured cell sheet in which cells are cultured on a surface of a cell culture support that is coated with a temperature responsive polymer having an upper or lower critical solution temperature ranging from 0° C. to 80° C. in water, including steps of: adjusting the temperature of the culture medium to a temperature below the lower critical solution temperature or above the upper critical solution temperature; bringing the cultured cell sheet in close contact with the carrier; and detaching the cultured cell sheet together with the carrier. | 2008-09-18 |
20080226693 | Apparatus and Method for Making a Polymeric Structure - The apparatus and method for preparing a polymeric structure from which a number of medical devices may be constructed is described. The structures are preferably formed from bioabsorbable materials using low temperature fabrication processes, whereby drugs or other bio-active agents are incorporated into or onto the device and degradation of the drugs or other agents during processing is minimized. The method includes preparing a solution of at least one bioabsorbable polymer and a solvent. The solution is then deposited onto a stage and converted into a structure. The solvent is evaporated from the structure. The dried solution forms a structure that is removed from the stage and further dried before being stored in an inert environment. Thereafter, a medical device such as a stent may be constructed from the structure. | 2008-09-18 |
20080226694 | Method for introducing superhydrophobic articles into the human body - An article to be inserted into the human body has a superhydrophobic surface. The superhydrophobic surface is coated with a water soluble thin but durable protective coat. One positioned inside the body the coating is rapidly dissolved by the blood or other fluids and exposes the superhydrophobic surface. To coat article the water based coating is mixed with a liquid capable of wetting the superhydrophobic surface but is still dissolvable or at least miscible in the coating. As an example, a glucose or sucrose solution in water is mixed with alcohol and used to coat the surface. After water and alcohol evaporation, a durable protective coat of sugar remains. After the coated article is inserted into the body, the coating is rapidly dissolved and absorbed by the body. | 2008-09-18 |
20080226695 | THIN FILM WITH NON-SELF-AGGREGATING UNIFORM HETEROGENEITY AND DRUG DELIVERY SYSTEMS MADE THEREFROM - The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. | 2008-09-18 |
20080226696 | Methods of improving learning abilities of aged companion animals - The present invention provides methods of improving learning ability of aged companion animals (such as aged dogs) by administering an effective amount of a carnitine and an effective amount of a lipoic acid. Also provided are kits and animal treats for improving learning ability of aged companion animals comprising effective amounts of carnitine and lipoic acid. | 2008-09-18 |
20080226697 | Patch for External Use with Elevated Content of Absorption Promoter in Pressure-Sensitive Adhesive Base - A pressure-sensitive adhesive composition for transdermal absorption which contains a drug and a transdermal absorption promoter for the drug, characterized by further containing polyvinylpyrrolidone so as to stabilize the transdermal absorption promoter contained in the adhesive composition. Thus, the transdermal absorption promoter can be prevented from vaporization or degradation and a patch for external use containing the transdermal absorption promoter at a high concentration in using can be provided. | 2008-09-18 |
20080226698 | Amorphous drug transdermal systems, manufacturing methods, and stabilization - The present invention refers to a transdermal delivery device comprising a backing layer, an adhesive matrix layer comprising a supersaturated concentration of an active agent substantially in amorphous form within the adhesive matrix, and a release liner. The present invention also refers to a method of preparing an adhesive matrix containing at least one supersaturated active agent substantially in amorphous form. Further, the present invention refers to a method to stabilize and a method to reestablish the meta-stable amorphous-drug transdermal system during its manufacturing, storing, shipping and handling process. | 2008-09-18 |
20080226699 | Method and System for Rapid Transdermal Administration - Invention relates to a method for transdermal delivery of a topically applied physiologically active agent comprising: providing a micro-projection apparatus comprising an array of microprojections ( | 2008-09-18 |
20080226700 | Medicated Gauze - The present invention relates to a medicated gauze containing as active ingredient, aliantoin, a Centella Asiatica extract and, optionally, an Urtica dioica extract. | 2008-09-18 |
20080226701 | MEDICATED PATCHES - An athletic head gear having a hard outer shell, at least one soft inner padding cushioning the head of a user from the hard outer shell, and a medicated patch including an adhesive layer contacting the soft inner padding, and a medicated layer for contacting the user's skin, where the medicated patch includes a medicament useful for treating or preventing acne. | 2008-09-18 |
20080226702 | Transdermal Delivery Form Disposal Systems and Methods - The extraction and use of residual opioids from transdermal dosage forms can be reduced by placement and fixation of used dosage forms onto a surface. The used dosage form can be fixed to the surface such that it cannot be removed without at least partially destroying the matrix containing the opioid, or such that the matrix containing the opioid is rendered at least partially inaccessible to opioid extraction methods. The disposal system for one or more opioid-containing transdermal delivery forms comprises at least one disposal surface for receiving the transdermal delivery form. The at least one disposal surface can comprise one or more structures for fixing a transdermal delivery form to the at least one surface. Alternatively, the transdermal delivery form comprises one or more structures for permanently fixing the transdermal delivery form to the surface. The disposal system can also be used for preventing or reducing diversion of opioids from transdermal delivery forms. | 2008-09-18 |
20080226703 | Human Growth Hormone Patch Formulations - The invention encompasses a transdermal patch formulation comprising hGH, at least one sugar, one amino acid or polyol, and a buffer, wherein the buffer maintains the pH of the formulation in the range of about 5 to about 9 and the formulation does not contain both glycine and mannitol. | 2008-09-18 |
20080226704 | Method of Producing Coated Fine Particles - The present invention provides a method of producing coated fine particles in which core fine particles is coated with a coating layer, which comprises the steps of preparing a liquid (liquid A) containing a polar organic solvent in which core fine particles are dispersed and a component constituting a coating layer is dissolved; preparing a liquid (liquid B) which is miscible with the liquid A and does not contain a polar organic solvent or contains a polar organic solvent in a ratio lower than that in the liquid A; and letting the liquid A flow from at least one inlet of a device for producing coated fine particles equipped with an in-line mixing means having two or more inlets and one or more outlet(s) and letting the liquid B flow from at least one remaining inlet to mix the liquids thereby coating the core fine particles with the coating layer. | 2008-09-18 |
20080226705 | GEL DELIVERY SYSTEM FOR ORAL ADMINISTRATION OF MEDICAMENTS - The invention relates to a swallowable delivery device fabricated from a composition including a hydrated polymeric matrix with gelatinous consistency, one or more active ingredients, and optionally one or more stiffening agent. The delivery device is of a size and shape amenable to swallowing with enhanced solubility and controlled release of the active ingredients. | 2008-09-18 |
20080226706 | Use of Repeat Sequence Protein Polymers in Personal Care Compositions - The present invention provides personal care compositions, and more particularly, personal care compositions comprising a bioactively effective amount of a repeat sequence protein polymer. In some particularly preferred embodiments, the present invention provides personal care compositions comprising an effective amount of at least one fragment of a repeat sequence protein polymer having bioactivity. | 2008-09-18 |
20080226707 | WNT compositions and methods of use thereof - Methods and compositions are provided for the therapeutic use of Wnt proteins, where the Wnt protein is inserted in the non-aqueous phase of a lipid structure. In some embodiments the Wnt protein is presented in its active conformation on an outer liposome membrane or micelle. Pharmaceutical compositions of the present invention can be administered to an animal for therapeutic purposes. In some embodiments of the invention, the compositions are administered locally, e.g. by injection at the site of an injury. For certain conditions it is desirable to provide Wnt activity for short periods of time, and an effective dose will be administered over a defined, short period of time. | 2008-09-18 |
20080226708 | Silicone Vesicles Containing Actives - Processes are disclosed for preparing silicone vesicle compositions and emulsions containing silicone vesicles, the compositions prepared therefrom, and formulated personal and healthcare products containing the silicone vesicles and emulsions compositions. | 2008-09-18 |
20080226709 | Phospholipid membrane preparation - The present invention aims at providing a phospholipid membrane preparation wherein an antigen or an allergen is bound onto the surface of a phospholipid membrane comprising a phospholipid containing an acyl group or a hydrocarbon group having 10 to 12 carbon atoms, and a stabilizer of a phospholipid membrane. The present invention provides a phospholipid membrane preparation having an immune response controlling function that suppresses production of IgE antibody to increases production of practically sufficient IgG antibody and usable as a vaccine that does not easily cause an allergic response. | 2008-09-18 |
20080226710 | UBIQUINOL AND ALPHA LIPOIC ACID COMPOSITIONS - The present invention is directed to compositions and methods of delivery of CoQ that is reduced in the presence of lipoic acid and, optionally a fatty acid and/or optionally in a monoterpene. The compositions that include the reduced CoQ can be formulated in soft gel capsules. | 2008-09-18 |
20080226711 | PHARMACEUTICAL COMPOSITIONS OF DULOXETINE - The present invention relates to solid oral pharmaceutical compositions of duloxetine, process for preparing such compositions and method of using such compositions. Preferably, the invention relates to a delayed release composition of duloxetine comprising a core comprising duloxetine, optional separating coat and an enteric coat. | 2008-09-18 |
20080226712 | Oral administration form for pyridin-2-ylmethylsulfinyl-1H benzimidazoles - The invention relates to an oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles and their salts, which comprises the active compound together with tablet disintegrants and is provided with a film coating customary per se for sustained-release compositions. | 2008-09-18 |
20080226713 | Controlled Release Pharmaceutical Compositions of Tolperisone for Oral Administration - The invention relates to a tolperisone-containing pharmaceutical preparation with controllable active-substance release for oral administration, characterised in that the active substance tolperisone and/or a pharmaceutical salt thereof is embedded in a pharmaceutically compatible material. By selecting the pharmaceutically compatible materials in the preparation and accordingly in the coating of a tablet or granule, a specific release of active substance can be adjusted which is matched to the special genotype in the metabolisation of tolperisone. At the same time, as a result of the very uniform and persistent release of tolperisone, the in vivo inversion of enantiomerically pure tolperisone that is known from the art can be adjusted in favour of the R(−)tolperisone which is prominent in muscle-relaxing therapy. | 2008-09-18 |
20080226714 | SUSTAINED-RELEASE TABLET FORMULATIONS OF PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR HAVING ENHANCED INTESTINAL DISSOLUTION - The present invention relates to sustained-release tablet formulations of piperazine-piperidine compounds, which can be useful in treating central nervous system disorders; to processes for their preparation; and to methods of using them. | 2008-09-18 |
20080226715 | THERAPEUTIC COMPOSITIONS AND METHODS - The present invention provides compositions, methods and kits for treating, preventing or reducing the risk of developing a CNS disorder. In general, the invention involves utilizing caffeine for preventing or alleviating pathological symptoms of a CNS disorder, such as headache, epilepsy, pain, Parkinson's disease, psychiatric disorders such as anxiety, bipolar disorder, depression, and schizophrenia, ADD, and ADHD. | 2008-09-18 |
20080226716 | AMINO ACID CONJUGATES PROVIDING FOR SUSTAINED SYSTEMIC CONCENTRATION OF GABA ANALOGUES - Compounds that provide for sustained systemic concentrations of GABA analogs following oral administration to animals are disclosed. Pharmaceutical compositions including, and methods using, such compounds are also disclosed. | 2008-09-18 |
20080226717 | Sublingual Coated Tablet - The present invention relates to a sublingual coated tablet and to a method for the preparation thereof. The tablet includes a core devoid of a pharmaceutically active substance, and a coating including at least one active substance. The preferred active substance is an opioid analgesic. | 2008-09-18 |
20080226718 | Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases - The use is described of compounds of formula (I) wherein A is chosen from a phenyl or a heterocyclic ring with 5 or 6 members containing up to two heteroatoms chosen from nitrogen, oxygen and sulfur, X and Y represent carbon or nitrogen, and R1-R6 are as described in the specification, in the prevention and/or treatment of inflammatory and autoimmune diseases. | 2008-09-18 |
20080226719 | Combination of Rosiglitazone and Donepezil for Improvement of Cognitive Function - Disclosed is a pharmaceutical composition comprising both rosiglitazone or a pharmaceutically acceptable salt thereof and donepezil or a pharmaceutically acceptable salt thereof which is of use in the treatment or prophylaxis of Alzheimer's disease or other dementias and mild cognitive impairment. Also disclosed is an oral dosage forms comprising rosiglitazone or a pharmaceutically acceptable salt thereof and donepezil or a pharmaceutically acceptable salt thereof. | 2008-09-18 |
20080226720 | Wound Healing Composition - The present invention relates to compositions and methods for tissue regeneration, particularly for treating skin lesions such as wounds. In one aspect, the invention provides a wound healing composition comprising living cells such as fibroblasts within a support matrix such as fibrin, in which the cells have a wound healing phenotype, and in which the composition is single layered and has been incubated for up to about 8 days to allow development of the wound healing phenotype. The compositions and methods of the invention are useful especially for assisting the process of wound healing, particularly chronic open lesions that are slow to heal or resistant to healing. | 2008-09-18 |
20080226721 | Porous Bodies and Method of Production Thereof - Porous bodies which are soluble or dispersible in non-aqueous media comprising a three dimensional open-cell lattice containing (a) 10 to 70% by weight of a polymeric material which is soluble in water immiscible non-aqueous media and (b) 30 to 90% by weight of a surfactant, said porous bodies having an intrusion volume as measured by mercury porosimetry of at least | 2008-09-18 |
20080226722 | Gel Composition Comprising Charged Polymers - Aqueous gel compositions are disclosed which are useful as drug carriers for controlled delivery applications, such as for parenteral depot formulations. The gels comprise ionically charged microparticles, and preferably mixtures of oppositely charged microparticles. The microparticles can be loaded with active compounds, such as therapeutic peptides and proteins. The gels can be prepared by combining oppositely charged microparticles in the presence of water. | 2008-09-18 |
20080226724 | Prevention of hydrogel viscosity loss - The present invention comprises methods and compositions for decreasing or preventing viscosity loss in hydrogels. | 2008-09-18 |
20080226725 | New and Advantageous Hydrogel Composition - New hydrogel, including a hydrogel containing cationic BSA is included in a vaccine to stimulate the immune system to increase the potency of the vaccine. | 2008-09-18 |
20080226726 | 3D-Cardiac Tissue Engineering For the Cell Therapy of Heart Failure - A pharmaceutical composition comprising biodegradable gel-based matrix, at least one active agent and stem cells able to differentiate into cardiac tissue under the form of a patch, for the treatment of heart failure due to myocardial infarction is disclosed. | 2008-09-18 |
20080226727 | Water-In-Silicone Oil Emulsion for Use as a Sunscreen Product - A water-in-silicone oil emulsion contains (i) in the range from 0.1 to 25% by weight of particles of metal oxide having a median particle volume diameter in dispersion in the range from 18 to 32 nm, (ii) 5 to 60% by weight of silicone oil, and (iii) greater than 20% by weight of water. The metal oxide particles are preferably incorporated into the emulsion in the form of an aqueous dispersion. The emulsion exhibits good skin feel, effective UV protection, stability and improved transparency. | 2008-09-18 |
20080226728 | Antimicrobial Nanoparticulate Additives Forming Non-Leachable Sustained Antimicrobial Polymeric Compositions - The present invention provides a particle comprising at least one aliphatic polymer having anti-microbially active quaternary ammonium groups chemically bound thereto. The particle of the invention may be used to inhibit populations of microorganisms and biofilms. Also provided are methods for the preparation of such particles and uses thereof for the inhibition of microorganisms. | 2008-09-18 |
20080226729 | STABLE POWDER FORMULATIONS OF ALUM-ADSORBED VACCINES - The present invention is directed to methods for preparing a stable powder formulation of an alum-adsorbed vaccine. The methods comprise atomizing a liquid formulation comprising an immunogen adsorbed onto an aluminum adjuvant to produce an atomized formulation, freezing the atomized formulation to produce frozen particles, and drying the frozen particles to produce dried powder particles. Pharmaceutical compositions comprising a stable powder formulation of an alum-adsorbed vaccine are also disclosed herein. The pharmaceutical compositions are stable at high temperatures and can be reconstituted in a pharmaceutically acceptable carrier to produce a reconstituted liquid vaccine that exhibits little or no particle agglomeration and retains immunogenicity. Methods of using the alum-adsorbed vaccine compositions for preventing and treating a disease in a subject, wherein the disease is associated with the particular immunogen, are further provided. | 2008-09-18 |
20080226730 | PARTICLES FOR INHALATION HAVING RAPID RELEASE PROPERTIES - The invention generally relates to formulations having particles comprising phospholipids, bioactive agent and excipients and the pulmonary delivery thereof. Dry powder inhaled insulin formulations are disclosed. Improved formulations comprising DPPC, insulin and sodium citrate which are useful in the treatment of diabetes are disclosed. Also, the invention relates to a method of for the pulmonary delivery of a bioactive agent comprising administering to the respiratory tract of a patient in need of treatment, or diagnosis an effective amount of particles comprising a bioactive agent or any combination thereof in association, wherein release of the agent from the administered particles occurs in a rapid fashion. | 2008-09-18 |
20080226731 | Pharmaceutical Compositions Comprising I Matinib and a Release Retardant - Sustained release pharmaceutical compositions that contain imatinib or a pharmaceutically acceptable salt thereof. The pharmaceutical compositions further contain a release retardant, for example a water soluble, a water swellable and/or a water insoluble polymer. The present invention also features a particularly useful process of making such sustained release pharmaceutical compositions by using an extruder. | 2008-09-18 |
20080226732 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS - Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions. | 2008-09-18 |
20080226733 | SPATIAL ARRANGEMENT OF PARTICLES IN A DRINKING DEVICE FOR ORAL DELIVERY OF PHARMACEUTICALS - The present invention relates to spatially arranging a plurality of particles in a device for the oral delivery of a pharmaceutical. In particular, the plurality of particles is utilized for the oral delivery of a pharmaceutical to a subject via the drinking device. | 2008-09-18 |
20080226735 | RARE EARTH METAL COMPOSITIONS FOR TREATING HYPERPHOSPHATEMIA AND RELATED METHODS - Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water. | 2008-09-18 |
20080226736 | Inhalatory Pharmaceutical Compositions in Form of Dry Powders, Solutions or Suspensions Obtained From the Same and Process for their Preparation - Inhalatory pharmaceutical composition comprising a drug, a soluble excipient and a surfactant, characterized by: said soluble excipient is present in an amount between 10% and less than 100% by weight; —the weight ratio between said surfactant and said drug is between 0.01 and 10; —the particle size of at least 50% of the particles of said powder is below 5 μm; —the bulk density d | 2008-09-18 |
20080226737 | Use of Calcitonin For the Treatment of Ra - The present invention relates to a novel use of calcitonin in rheumatoid arthritis, and to methods of treating and/or preventing rheumatoid arthritis and conditions associated therewith in mammals, particularly humans. In particular, a method is provided of preventing or/and treating rheumatoid arthritis in a patient in need thereof comprising administering to said patient a therapeutically effective amount of calcitonin, e.g. salmon calcitonin in free form or salt form, in a pharmaceutically acceptable oral delivery form, wherein the therapeutically effective amount of a calcitonin is delivered orally in a composition comprising the calcitonin and a delivery agent for calcitonin. | 2008-09-18 |
20080226738 | Sustained-Released Pellet Formulation of Alpha1-Receptor Antagonist and Process For the Preparation Thereof - A sustained-release pellet formulation comprising: a pellet core comprising an α1-receptor antagonist, a pellet-forming substance and a pharmaceutically acceptable excipient and a coating layer comprising an enteric coating substance and a water-insoluble polymer, which is coated on said pellet core maintains a therapeutically effective drug level in the blood for a sufficient time without an initial burst and sustains the release of the drug even in the small intestine due to the water-insoluble polymer in the coating layer | 2008-09-18 |
20080226739 | Hierarchically self-assembling linear-dendritic hybrid polymers for delivery of biologically active agents - A linear-dendritic hybrid polymer for encapsulating biologically active materials. The hybrid polymer includes a ligand for a predetermined target, a dendron, and a polyethylene glycol (PEG) chain linking the ligand to the dendron. | 2008-09-18 |
20080226740 | Marine algal extracts comprising marine algal polysaccharides of low degree polymerizaton, and the preparation processes and uses thereof - Disclosed herein are marine algal extracts containing marine algal polysaccharides of low degree polymerization, and nanoparticles fabricated from the extracts. Preparation processes and applications of the marine algal extracts and the nanoparticles are also disclosed. | 2008-09-18 |
20080226741 | Cross-linked Polymer Particles - Biodegradable cross-linked particles, as well as related compositions and methods, are disclosed. | 2008-09-18 |
20080226742 | Compositions for Drug Delivery - Substantially non-porous polymeric microparticles comprising a hydrophobic polymer and a plasticizer, and containing therein a bioactive or bioinactive agent. | 2008-09-18 |
20080226743 | Agent for Photodynamic Therapy Containing Porous Silicon and Method of Quantitative Measurement of Reactive Oxygen Species Produced Therefrom - The present invention relates to an agent for photodynamic therapy (PDT) containing porous silicon (PSi) and a method of quantitative measurement of reactive oxygen species (ROS) produced therefrom. Particularly, it is expected that the present invention will contribute to the development of cancer treatment without side effects by suggesting PSi, a safe and reliable new cancer drug that can destroy cancer cells through generating sufficient heat with little ROS produced if the PSi is used as nanobomb for a new PDT that kills cancer cells with heat or explosion. In addition, it is expected that the present invention will provide a reliable and reproducible method for quantitative measurement of a very small amount of ROS produced therefrom through an XRD analysis. | 2008-09-18 |
20080226744 | DIETARY SUPPLEMENT AND RELATED METHOD - A composition including a unique combination of fruits, vegetables, herbs, and optionally vitamins, minerals and specialty ingredients. The composition can include a fruit ingredient, a vegetable ingredient and an herbal ingredient, wherein the fruit ingredient is at least one of pomegranate and citrus bioflavonoids, wherein the vegetable ingredient, is at least one of asparagus, lutein, lycopene and watercress, and wherein the herbal ingredient is at least one of basil, oregano and rosemary. The composition can be administered to subjects to correct a dietary deficiency of phytochemicals and other nutrients, improve plasma concentrations of antioxidant nutrients, and increase the activity of genetic mechanisms for DNA repair and stability. | 2008-09-18 |
20080226745 | Products Containing Highly Unsaturated Fatty Acids for Use by Women During Stages of Preconception, Pregnancy and Lactation/Post-Partum - A method and product for improving maternal and child health through nutrition. Omega-6 fatty acid and/or omega-3 fatty acid are provided to a woman and/or child prior to, during and/or after pregnancy to improve the health of the woman and her child. The ratios of the omega-6 and omega-3 fatty acids vary during various stages, e.g., pre-pregnancy, pregnancy and post-pregnancy. The omega-6 and omega-3 fatty acids can be in a variety of forms, such as at least one of highly purified algal oil comprising 70% by weight or more of the desired HUFA, triglyceride oil combined with phospholipid, phospholipid, protein and phospholipid combination, or dried marine microalgae. | 2008-09-18 |
20080226746 | NUTRITIONAL SUPPLEMENT FOR WOMEN - A nutritional supplement comprising a variety of vitamins and minerals is described. A nutritional supplement comprising between about 1 mg and about 5 mg of vitamin B | 2008-09-18 |
20080226747 | PHARMACEUTICAL FORMULATIONS COMPRISING SALTS OF A PROTEIN KINASE INHIBITOR AND METHODS OF USING SAME - The present invention relates to pharmaceutical formulations comprising the protein kinase inhibitor, MP470, and methods of using same in treating conditions involving undesirable cell proliferation, such as cancer. | 2008-09-18 |
20080226748 | Stabilized Chlorine Dioxide and Hypochlorous Acid in a Liquid Biocide - A liquid biocide containing stabilized chlorine dioxide and hypochlorous acid for various uses, including use as a teat dip or dairy animals. The stable, prophylactic biocide consists essentially of 0.10-20.0% by weight of a chlorite salt, 0.1-3.0% by weight of an acid, 0.10-2.0% by weight of an alkaline agent, and the balance water. Chlorite salt reacts with the acid to form germicidal chlorine dioxide and hypochlorous acid. The acid constituency and the alkaline agent constituency regulate the pH of the solution such that the biocide is stable when mixed for a period greater than two months. The present disclosure also includes a method of producing a stable, prophylactic biocide for dairy cattle, the method comprising 0.10-20.0% by weight of a chlorite salt, 0.10-3.0% by weight of an acid, 0.10-2.0% by weight of an alkaline agent, and the balance water in a container, and sealing the container. In the method, the acid and alkaline agent constituencies regulate the pH of the solution such that the formation of hydronium ions from the acid is correspondingly regulated to stabilize the solution for a period greater than two months from the date of sealing. | 2008-09-18 |
20080226749 | Pharmaceutical composition for inhibiting the syndrome of snoring and preparation thereof - The present invention discloses a pharmaceutical composition for inhibiting a snore symptom, which comprises medicinal material of | 2008-09-18 |
20080226750 | Methods, Compositions and Articles of Manufacture for Treating Shock and Other Adverse Conditions - The present invention concerns the use of active compounds for inducing apnea and treating shock, in addition to enhancing the survivability of a subject. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving these effects. | 2008-09-18 |
20080226751 | PHARMACEUTICAL COMPOSITION CONTAINING NITRATE SOURCE AND AN ACIDIFYING AGENT FOR TREATING SKIN ISCHAEMIA - The use of acidified nitrate as an agent to produce local production of nitrate oxide at the skin surface is described in the treatment of peripheral ischaemia and associated conditions. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at the environment. A barrier consisting of a membrane allows diffusions of the nitrate ions while preventing direct contact of the skin and acidifying agent. Amongst the many potential applications for the invention is the management of chronic skin wounds, peripheral ischaemia conditions such as Raynaud's phenomenon. Compositions and methods of use for these applications are described. | 2008-09-18 |
20080226752 | KITS OF HYDRALAZINE COMPOUNDS AND ISOSORBIDE DINITRATE AND/OR ISOSORBIDE MONONITRATE - The present invention provides methods of treating and preventing mortality associated with heart failure in an African American patient with hypertension and improving oxygen consumption, quality of life and exercise tolerance by administering a therapeutically effective amount of at least one hydralazine compound and at least one of isosorbide dinitrate and isosorbide mononitrate, and, optionally, one or more compounds, such as, for example, a digitalis, a diuretic compound, or a compound used to treat cardiovascular diseases. In the present invention, the hydralazine compound is preferably hydralazine or a pharmaceutically acceptable salt thereof. Preferred methods of the invention comprise administering hydralazine or a pharmaceutically acceptable salt thereof and isosorbide dinitrate. | 2008-09-18 |
20080226753 | Method of Reducing Insect Resistant Pests in Transgenic Crops - The present invention discloses Resistance Management (RM) practices that are critical to safeguarding | 2008-09-18 |
20080226754 | METHOD FOR TREATMENT OF CARTILAGE DISORDERS WITH CENTELLA EXTRACT - The invention is a method for the treatment of mammalian articular cartilage disorders, inflammatory joint disease, trauma-related cartilage injuries, and degenerative disc disease. The method involves treating the affected area with a composition containing a therapeutically effective dose of | 2008-09-18 |
20080226755 | Composition to enhance the bioavailability of curcumin - A composition for enhanced bioavailability of curcumin including purified curcuminoid and purified essential oil of turmeric. A method to prepare a composition for enhanced bioavailability of curcumin having purified curcuminoid and purified essential oil of turmeric. | 2008-09-18 |
20080226756 | COMPOSITIONS COMPRISING A C-GLYCOSIDE COMPOUND - The present invention relates, in particular, to:
| 2008-09-18 |
20080226757 | Use of a Ginkgo Complexes for the Enhancement of Cognitive Functions and the Alleviation of Mental Fatigue - The invention is directed to the use of Ginkgo complexed with phosphatidylserine for the manufacture of a medicament or a dietary supplement for the enhancement of cognitive function and mental fatigue, i.e. to improve the factors related therewith such as to improve the speed of memory and memory quality, to increase accuracy and attention in activities in normal, healthy subjects, to prevent deterioration of the speed and quality of memory in people with decreased cognitive functions and to counteract cognitive fatigue, having also an influence on the mood, particularly in healthy children, young adults, middle-aged and/or old people. It is further provided the use of the Ginkgo phosphatidylserine complex for the treatment and prevention of a disease related with a decrease of the cognitive function and mental fatigue such as Dementia, e.g. Alzheimer's Disease. | 2008-09-18 |
20080226758 | Lipoxygenase and Cyclooxygenase Inhibition - The present invention relates to methods, compositions and their constituents for inhibiting 5-Lipoxygenase (5-LO), 15-Lipoxygenase (15-LO), cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), in living organisms. More particularly, the present invention relates to methods and compositions involving the inhibition of 5-Lipoxygenase (5-LO), 15-Lipoxygenase (15-LO), cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), using processed | 2008-09-18 |
20080226760 | ANTIMICROBIAL COMPOSITION AND USE THEREOF - This invention relates to compositions with broad antimicrobial activity against bacteria, fungi, and protozoans. The compositions and methods of the present invention can be used in the prevention and treatment of pathogenic processes in people and animals by any administration method (oral, topical, or parenteral), as a performance improver in animals, infection controller in fermentations, and preserver of grains, seeds, and food for animals and/or people. | 2008-09-18 |
20080226761 | Foil balloon for enabling customized design to print on either side and method of manufacturing same - The present invention is to provide a foil balloon for enabling a user to print a customized design on each of both sides, which comprises a carrier (e.g. paper) comprising a central opening, and an upper second foil and a lower first foil releasably attached onto top and bottom surfaces of the carrier respectively, wherein a valve is provided between the first and second foils and is disposed correspondingly to an inner edge of the opening, a heat sealed portion is formed around the inner edge of the opening on each of the first and second foils after heat sealing the first and second foils together with the valve being sealed by the heat sealed portions of the first and second foils, perforations is punched on each of the first and second foils at a position between the heat sealed portion and the inner edge of the opening. | 2008-09-18 |
20080226762 | Injection control apparatus - An injection control apparatus includes an injection member; a drive section for injection; an injection-speed detection processing section which detects injection speed; an injection-pressure detection processing section which detects injection pressure; and a drive control processing section which drives the drive section for injection on the basis of the injection speed and the injection pressure to thereby perform pressure control before start of charging of a molding material into a cavity, and speed control after the start of charging of the molding material into the cavity. Since the drive section is driven on the basis of the injection speed and the injection pressure such that pressure control is performed before start of charging of a molding material into a cavity, and speed control is performed thereafter, the pressure of the cavity after the molding material has entered the cavity becomes stable and uniform. | 2008-09-18 |
20080226763 | Preform-Supply Device Comprising a Device for the Selective Removal of Incorrectly-Positioned Longitudinal Preforms - The invention proposes a system ( | 2008-09-18 |
20080226764 | Injection Molding Nozzle | 2008-09-18 |
20080226765 | Injection System - Injection system with closing rod ( | 2008-09-18 |
20080226766 | Dog Periodontitis - A method of determining susceptibility to periodontitis in a Shih Tzu dog, Yorkshire Terrier dog or a dog of a breed that is genetically related to the Shih Tzu or Yorkshire Terrier breed, comprises: a) typing the nucleotide present in the genome of the dog at or at a position equivalent to each of the following: position 201 of SEQ ID NO: 2 (SNP_02), or a position that is in linkage disequilibrium with this position,—position 201 of SEQ ID NO: 4 (SNP_04), or a position that is in linkage disequilibrium with this position, and position 201 of SEQ ID NO: 9 (SNPJ39), or a position that is in linkage disequilibrium with this position, and b) thereby determining whether the dog is susceptible to periodontitis. | 2008-09-18 |
20080226767 | UNIFORMLY MOIST CHEESE - The invention provides moist cheeses of uniform composition that are readily and inexpensively made by acidifying milk prior to beginning the cheese making process. | 2008-09-18 |
20080226768 | Method of producing non-bovine chymosin and use hereof - A method of recombinantly producing a non-bovine pre-prochymosin, prochymosin or chymosin derived from ruminant species including deer species, buffalo species, antelope species, giraffe species, ovine species and caprine species; | 2008-09-18 |
20080226769 | Process For Producing Soybean Protein and Process For Producing Processed Meat Food Using the Soybean Protein - The present invention aims to provide a process for producing a soybean protein wherein transglutaminase is used to improve both the gel property and the emulsifying property. Namely, it is a process for producing a soybean protein comprising treating a soybean protein solution or soybean protein slurry with transglutaminase, wherein a heat treatment is performed before or after the treatment with transglutaminase. | 2008-09-18 |
20080226770 | BEVERAGE PRODUCTS HAVING STEVIOL GLYCOSIDES AND AT LEAST ONE ACID - Beverage products are provided which include rebaudioside A, erythritol, and an acid component. The beverage product has a titratable acidity in the range of about 8.75 to about 10.25, and a pH in the range of about 2.8 to about 3.3. Beverage products disclosed herein achieve a proper sweet/tart ratio to increase sweetness and to reduce tartness and bitterness of beverages made with natural sweeteners. | 2008-09-18 |